Longboard Pharmaceuticals Inc (LBPH)

Currency in USD
59.980
0.000(0.00%)
Closed·
Showing Longboard Pharmaceuticals historical data. For real-time data please try another search
Day's Range
59.98060.030
52 wk Range
15.64060.030
Key Statistics
Prev. Close
59.98
Open
59.99
Day's Range
59.98-60.03
52 wk Range
15.64-60.03
Volume
-
Average Volume (3m)
1.94M
1-Year Change
70.93%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Longboard Pharmaceuticals Inc Company Profile

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California. As of December 2, 2024, Longboard Pharmaceuticals, Inc. operates as a subsidiary of Langkawi Corporation.

Longboard Pharmaceuticals Inc SWOT Analysis


Bexicaserin's Promise
Explore Longboard Pharmaceuticals' lead compound bexicaserin, a potential game-changer in treating developmental and epileptic encephalopathies with billion-dollar market potential.
Pipeline Progress
Delve into Longboard's advancing clinical trials, including the upcoming Phase 3 epilepsy program for bexicaserin and early-stage developments of LP659 for neuroinflammatory conditions.
Market Disruption
Learn how bexicaserin's favorable safety profile could reshape the competitive landscape, potentially outperforming existing treatments like Fintepla in efficacy and long-term safety.
Analyst Optimism
Discover why analysts are bullish on Longboard, with price targets ranging from $60 to $90, reflecting confidence in the company's innovative approach to neurological treatments.
Read full SWOT analysis

Earnings

Latest Release
Feb 27, 2025
EPS / Forecast
-0.63 / -0.6225
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

LBPH Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.